 |
|
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online 2022 Nov 22 DOI: https://doi.org/10.3350/cmh.2022.0348
|
|
Citations to this article as recorded by
 Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2025; 120(2): 410. CrossRef Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role
Mohammadjavad Sotoudeheian
Current Protein & Peptide Science.2025; 26(1): 6. CrossRef Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017–2020
Yuou Ying, Yuan Ji, Ruyi Ju, Jinhan Chen, Mingxian Chen
BMC Gastroenterology.2025;[Epub] CrossRef Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib
Won Sohn
Clinical and Molecular Hepatology.2025; 31(1): 277. CrossRef The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies
Renee Hernandez, Natasha S. Garcia-Rodriguez, Marco A. Arriaga, Ricardo Perez, Auwal A. Bala, Ana C. Leandro, Vince P. Diego, Marcio Almeida, Jason G. Parsons, Eron G. Manusov, Jacob A. Galan
Frontiers in Medicine.2025;[Epub] CrossRef Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases
Patrizia Burra, Calogero Cammà, Pietro Invernizzi, Fabio Marra, Maurizio Pompili
Annals of Hepatology.2025; 30(1): 101900. CrossRef Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Jeayeon Park, Su Jong Yu
Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis
Chunxiang Zhang, Hua Ma, Daniel DeRoche, Eric M. Gale, Pamela Pantazopoulos, Nicholas J. Rotile, Himashinie Diyabalanage, Valerie Humblet, Peter Caravan, Iris Y. Zhou
npj Imaging.2025;[Epub] CrossRef Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning
Hong Lu, Ziyong Mao, Mengyao Zheng, Min Zhang, Heqing Huang, Yiling Chen, Long Lv, Zutao Chen, Akif Altınbas,
PLOS One.2025; 20(5): e0324972. CrossRef Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Xiangchang Zeng, Deliang Huang, Zhibin Zhu, Qingxian Cai, Yang Yang, Hongzhou Lu, Jun Chen
Frontiers in Pharmacology.2025;[Epub] CrossRef Obesity as a mediator in the association between urinary polycyclic aromatic hydrocarbon exposure and liver fibrosis risk in US adults
Wang Guo, Beizhu Ye, Xiaoli Ma, Jinying Liu, Yanqin Yue, Xingyuan Yang, Jian Hou, Xiuling Li, Xiaoying Luo
Environmental Science: Processes & Impacts.2025;[Epub] CrossRef The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu
Journal of Gastroenterology and Hepatology.2024; 39(1): 193. CrossRef Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease
Jaejun Lee, Seungmyeon Choi, Seong-Hyun Cho, Hyun Yang, Pil-Soo Sung, Si-Hyun Bae
Diagnostics.2024; 14(4): 393. CrossRef Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283. CrossRef Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis
Marinela Sînziana Tudor, Veronica Gheorman, Georgiana-Mihaela Simeanu, Adrian Dobrinescu, Vlad Pădureanu, Venera Cristina Dinescu, Mircea-Cătălin Forțofoiu
Metabolites.2024; 14(4): 198. CrossRef Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, Alexandra Kraut, Justine Barthelon, Nathalie Sturm, Hélène Borges, Salomé Biennier, Marie Courçon, Marc de Saint Loup, Victoria Mignot, Charlotte Costentin, Thomas Burger, Yohann Couté, Christophe Bru
Biomarker Research.2024;[Epub] CrossRef Aspartate Aminotransferase to Platelet Ratio Index (APRI) as a Predictor of Metabolic Syndrome (MetS) Development in Individuals With Type 2 Diabetes Mellitus
Amir Jalisi, Rijad Jahić, Avdo Kurtović, Miralem Đešević, Azra Husić-Selimović, Enisa Hodžić, Edina Lazović Salčin, Orhan Lepara, Almir Fajkić
Cureus.2024;[Epub] CrossRef Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease
Mohammadjavad Sotoudeheian
Protein & Peptide Letters.2024; 31(4): 290. CrossRef Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis
Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
Clinical and Molecular Hepatology.2024; 30(Suppl): S106. CrossRef Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun
Clinical and Molecular Hepatology.2024; 30(Suppl): S147. CrossRef Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease
Jae Seung Chang, Jhii-Hyun Ahn, Moon Young Kim, Kyu-Sang Park
Scientific Reports.2024;[Epub] CrossRef Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Diren Beyoğlu, Yury V. Popov, Jeffrey R. Idle
International Journal of Molecular Sciences.2024; 25(23): 12809. CrossRef Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Maamon Basheer, Mohamed Naffaa, Nimer Assy
Clinical and Molecular Hepatology.2023; 29(2): 398. CrossRef Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study)
Andrew Collier, Christopher Curran, Lyall Cameron, Sarah H. Wild, Christopher D. Byrne
Diabetes, Obesity and Metabolism.2023; 25(9): 2659. CrossRef Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM
Tina Reinson, Ryan M Buchanan, Christopher D Byrne
Expert Review of Endocrinology & Metabolism.2023; 18(5): 355. CrossRef Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel
World Journal of Gastroenterology.2023; 29(32): 4831. CrossRef Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
Abena S Agyeman, Abbas Bandukwala, Khaled Bouri, Jessica Hawes, Daniel M Krainak, Samir Lababidi, William B Mattes, Elena V Mishina, Phillip Turfle, Sue-Jane Wang, Theresa Thekkudan
Biomarkers in Medicine.2023; 17(11): 523. CrossRef The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
Diagnostics.2023; 13(21): 3316. CrossRef Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis
Yan Li, Meng-Jun Zhang, Xue-Hong Wang, Su-Hua Li
Biomedical Reports.2023;[Epub] CrossRef
|